	US 12,109,236 B2
	Manipulating ARID5B expression in immune cells to promote metabolism, survival, and function
Jeffrey Steven Miller, Minneapolis, MN (US); and Frank Martin Cichocki, Minneapolis, MN (US)
Assigned to Regents of the University of Minnesota, Minneapolis, MN (US)
Appl. No. 17/055,525
Filed by REGENTS OF THE UNIVERSITY OF MINNESOTA, Minneapolis, MN (US)
PCT Filed May 8, 2019, PCT No. PCT/US2019/031296 § 371(c)(1), (2) Date Nov. 13, 2020, PCT Pub. No. WO2019/221991, PCT Pub. Date Nov. 21, 2019.
Claims priority of provisional application 62/670,962, filed on May 14, 2018.
Prior Publication US 2021/0154232 A1, May 27, 2021
Int. Cl. A61K 35/17 (2015.01); C07K 14/47 (2006.01); C07K 14/725 (2006.01); C12N 5/00 (2006.01); C12N 5/0783 (2010.01)

CPC A61K 35/17 (2013.01) [C07K 14/47 (2013.01); C07K 14/7051 (2013.01); C12N 5/0646 (2013.01); C12N 2510/00 (2013.01)]

12 Claims

1. An isolated population of Natural Killer (NK) cells comprising a recombinant nucleic acid encoding an AT-rich interaction domain 5B (ARID5B) polypeptide operably linked to a heterologous promoter, wherein the NK cells exhibit increased expression of said ARID5B polypeptide relative to a wild-type NK cell.